Difference between revisions of "PHACTR2-AS1"
(Created page with "PHACTR2-AS1 can promote the proliferation,invasion and metastasis of HCC via the PTEN/PI3K/AKT signaling pathway.<ref name="ref2" /> ==Annotated Information== ===Name===...") |
(→Regulation) |
||
| Line 19: | Line 19: | ||
Down-regulation of LncRNA PHACTR2-AS1 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma.<ref name="ref2" /> | Down-regulation of LncRNA PHACTR2-AS1 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma.<ref name="ref2" /> | ||
===Regulation=== | ===Regulation=== | ||
| − | [[File: PHACTR2-AS1. | + | [[File: PHACTR2-AS1-reg.png|thumb|px|PHACTR2-AS1 Promotes HCC Cell Migration, Invasion, and Proliferation through the ERK- and AKT-Signaling Pathways.<ref name="ref2"/>]] |
A regulatory network of ERK and AKT signaling through PHACTR2-AS1 indicate that PHACTR2-AS1 may be a potential target for treating HCC.<ref name="ref1" /> | A regulatory network of ERK and AKT signaling through PHACTR2-AS1 indicate that PHACTR2-AS1 may be a potential target for treating HCC.<ref name="ref1" /> | ||
| − | PHACTR2-AS1 knockdown inhibited the proliferation and metastasis of HCC cells in vitro.NR027113 knock-down to inhibit the activity of the PI3K/Akt signaling pathway and restrain the EMT process.<ref name="ref2" /> | + | PHACTR2-AS1 knockdown inhibited the proliferation and metastasis of HCC cells in vitro.NR027113 knock-down to inhibit the activity of the PI3K/Akt signaling pathway and restrain the EMT process.<ref name="ref2" /> |
| + | |||
===Expression=== | ===Expression=== | ||
PHACTR2-AS1 positively regulated the expression of epithelial mesenchymal transition (EMT)-related markers c-Myc and Cyclin D1, as well as the activation of the ERK- and AKT-signaling pathways.<ref name="ref1" /> | PHACTR2-AS1 positively regulated the expression of epithelial mesenchymal transition (EMT)-related markers c-Myc and Cyclin D1, as well as the activation of the ERK- and AKT-signaling pathways.<ref name="ref1" /> | ||
Latest revision as of 04:25, 22 February 2021
PHACTR2-AS1 can promote the proliferation,invasion and metastasis of HCC via the PTEN/PI3K/AKT signaling pathway.[1]
Contents
Annotated Information
Name
Approved symbol:PHACTR2-AS1
Approved name:PHACTR2 antisense RNA 1
HGNC ID:40943
Alias symbol:NR027113|lncIHS
RefSeq ID:NR_027114
LncBook ID:HSALNG0054038
Characteristics
Please input information here.
Function
PHACTR2-AS1 Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3β-Signaling Pathways.[2] Down-regulation of LncRNA PHACTR2-AS1 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma.[1]
Regulation
A regulatory network of ERK and AKT signaling through PHACTR2-AS1 indicate that PHACTR2-AS1 may be a potential target for treating HCC.[2] PHACTR2-AS1 knockdown inhibited the proliferation and metastasis of HCC cells in vitro.NR027113 knock-down to inhibit the activity of the PI3K/Akt signaling pathway and restrain the EMT process.[1]
Expression
PHACTR2-AS1 positively regulated the expression of epithelial mesenchymal transition (EMT)-related markers c-Myc and Cyclin D1, as well as the activation of the ERK- and AKT-signaling pathways.[2] PHACTR2-AS1 can promote the proliferation, invasion and metastasis of HCC via the PTEN/PI3K/AKT signaling pathway.[1]
Diseases
Hepatocellular carcinoma (HCC)[2]
Labs working on this lncRNA
- Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Research Center of Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China; Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.[2]
- Department of General Surgery, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China.[2]
- Surgical Bioengineering Laboratory, Department of Surgery, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA.[2]
- Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Research Center of Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China; Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China. Electronic address: zhouzhy26@mail2.sysu.edu.cn.[2]
- Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Research Center of Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. jiewsysu@163.com.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Chen Z, Zhou ZY, He CC, Zhang JL, Wang J, Xiao ZY. Down-regulation of LncRNA NR027113 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7222-7232. doi: 10.26355/eurrev_201811_16256.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Chen Z, Yu W, Zhou Q, Zhang J, Jiang H, Hao D, Wang J, Zhou Z, He C, Xiao Z. A Novel lncRNA IHS Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3β-Signaling Pathways. Mol Ther Nucleic Acids. 2019 Jun 7;16:707-720. doi: 10.1016/j.omtn.2019.04.021. Epub 2019 Apr 30.
